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Abstract
Accurate preoperative staging and restaging of mediastinal lymph nodes in patients with potentially resectable non-small-cell lung cancer
(NSCLC) is of paramount importance. In 2007, the European Society of Thoracic Surgeons (ESTS) published an algorithm on preoperative
mediastinal staging integrating imaging, endoscopic and surgical techniques. In 2009, the International Association for the Study of Lung
Cancer (IASLC) introduced a new lymph node map. Some changes in this map have an important impact on mediastinal staging. Moreover,
more evidence of the different mediastinal staging technique has become available. Therefore, a revision of the ESTS guidelines was needed. In
case of computed tomography (CT)-enlarged or positron emission tomography (PET)-positive mediastinal lymph nodes, tissue conﬁrmation is
indicated. Endosonography [endobronchial ultrasonography (EBUS)/esophageal ultrasonography (EUS)] with ﬁne-needle aspiration (FNA) is
the ﬁrst choice (when available), since it is minimally invasive and has a high sensitivity to rule in mediastinal nodal disease. If negative, surgical
staging with nodal dissection or biopsy is indicated. Video-assisted mediastinoscopy is preferred to mediastinoscopy. The combined use of
endoscopic staging and surgical staging results in the highest accuracy. When there are no enlarged lymph nodes on CT and when there is no
uptake in lymph nodes on PET or PET–CT, direct surgical resection with systematic nodal dissection is indicated for tumours ≤3 cm located in
the outer third of the lung. In central tumours or N1 nodes, preoperative mediastinal staging is indicated. The choice between endoscopic
staging with EBUS/EUS and FNA or video-assisted mediastinoscopy depends on local expertise to adhere to minimal requirements for staging.
For tumours >3 cm, preoperative mediastinal staging is advised, mainly in adenocarcinoma with high standardized uptake value. For restaging,
invasive techniques providing histological information are advisable. Both endoscopic techniques and surgical procedures are available, but
their negative predictive value is lower compared with the results obtained in baseline staging. An integrated strategy using endoscopic staging
techniques to prove mediastinal nodal disease and mediastinoscopy to assess nodal response after induction therapy needs further study.
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INTRODUCTION
For patients with non-small-cell lung cancer (NSCLC) and no
systemic metastasis, mediastinal staging is very important as it pro-
vides accurate information on the extent of the disease, guides the
choice of treatment and determines the patient’s prognosis.
In 2007, the European Society of Thoracic Surgeons (ESTS) pub-
lished an algorithm on preoperative mediastinal staging based on
the current available literature [1]. These guidelines integrated
imaging, endoscopic and surgical techniques. They were widely
used and have been prospectively validated. Their negative pre-
dictive value (NPV) is 0.94 [2].
However, since 2007, there have been substantially more infor-
mation and evidence on mediastinal staging techniques. In 2009,
the International Association for the Study of Lung Cancer (IASLC)
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introduced a new lymph node map of the lungs and mediastinum
that resulted from an international and multidisciplinary consen-
sus [3]. Some new changes in this map have an important impact
on mediastinal staging. Moreover, new insights into the import-
ance of restaging and techniques for mediastinal restaging have
become available. Therefore, the ESTS Council approved the ini-
tiative by the working group to revise and update the previous
guidelines on mediastinal staging.
METHODOLOGY
There were several meetings of the working group. The project
was discussed in the Council at the ESTS meeting in Essen ( June
2012). There were several meetings (Essen, Zürich, Brussels and
Birmingham) where the participants presented their experience
and discussed the relevant literature published since 2007. Initial
ﬁndings were presented and discussed at the ESTS meeting in
Birmingham (May 2013). The ﬁnal paper was put on the website
for discussion by all ESTS members. Their remarks were discussed
and included in the ﬁnal manuscript.
For recommendations, a level of evidence and grading of rec-
ommendation is given. This was adapted from the Infectious
Diseases Society of America–United States Public Health Service
grading system (Table 1) [4].
It is evident that both in primary staging and in restaging, not
every technique is available in every centre. Therefore, staging
and restaging techniques can differ between different countries
and centres.
IMPACT OF NEW IASLC LYMPH NODE MAP
There are several modiﬁcations compared with the previous
Naruke and Mountain and Dresler maps [5, 6], but probably the
most important modiﬁcation from the clinical point of view is the
shift of the anatomical mediastinal midline to the left paratracheal
margin, the so-called mediastinal oncological midline [3]. This
change is important to be understood by radiologists, bronchos-
copists, nuclear medicine specialists and surgeons because they
have to locate the nodes correctly. The clinical implications of this
new deﬁnition of the mediastinal midline, that affect exclusively
nodal stations 2R, 2L, 4R and 4L (for the rest of the nodal stations,
the mediastinal midline remains unchanged) is that involved pre-
tracheal lymph nodes and lymph nodes on the left of the anatom-
ical midline but on right side of the oncological midline are
classiﬁed as N2 in case of right-lung tumours but as N3 in case of
left-lung tumours.
Another important modiﬁcation for mediastinal staging is that
the anatomical borders of the lymph node (LN) stations are clearly
deﬁned. This is especially relevant for the lower border of stations
4R and 4L. For the right lower paratracheal lymph nodes (station
4R), the lower border is the lower margin of the azygos vein. On the
left side, the lower border of the left paratracheal lymph nodes
(station 4L) is the upper rim of the left pulmonary artery. By cervical
mediastinoscopy (and by endoscopic techniques), the lymph nodes
below the azygos vein and below the upper rim of the pulmonary
artery can be biopsied and they should be labelled, respectively, as
10R and 10L (Fig. 1 and Table 2 with permission from IASLC).
Deﬁnition of nodal zone and nodal station
A nodal zone is an anatomical area that includes one or several
neighbouring nodal stations. The supraclavicular and the subcar-
inal zones include one nodal station each, station 1 and station 7,
respectively. However, the limits of both nodal stations 1 and 7
are wider than they used to be in the previous maps. The other
nodal zones include two, three or six nodal stations. It is import-
ant to realize that, in theory, a single N2 zone may have from one
to multiple nodes involved in one or several nodal stations,
and the nodes may be small or large. The concept of nodal zones
is of especial value for those patients who will not undergo surgi-
cal treatment. For those receiving chemotherapy, radiotherapy
or their combination, the precise anatomical location of the
nodes involved is not so important. So, the nodal zones help
locate nodal involvement without having to deﬁne the exact ana-
tomical location of the nodes. However, nodal stations are im-
portant for those patients in whom surgical treatment is required.
Precise nodal location is important preoperatively to guide surgi-
cal treatment, and also intra- and postoperatively to indicate
further treatment. This is especially relevant in the upper medi-
astinal zone. Whether the right or the left paratracheal nodes
are involved or not is important to conﬁrm or rule out N2 or
N3 disease and to select patients for surgical (multimodality)
treatment.
Table 1: Level of evidence and grading of recommendation
Level of evidence
I Evidence from at least one large randomized controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted
randomized trials without heterogeneity
II Small randomized trials or large randomized trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials with
demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports and experts opinions
Grading of recommendation
A Strong evidence for efficacy with a substantial clinical benefit, strongly recommended
B Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs,…), optional
D Moderate evidence against efficacy or for adverse outcomes, generally not recommended
E Strong evidence against efficacy or for adverse outcome, never recommended
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RATIONALE FOR PREOPERATIVE MEDIASTINAL
NODAL STAGING
The current guidelines for the treatment of lung cancer are deter-
mined by the clinical status of the mediastinal nodes. The aim of
mediastinal staging is to exclude with the highest certainty and the
lowest morbidity patients with mediastinal nodal disease since
these patients will not beneﬁt from upfront surgery [7, 8].
There is controversy regarding the best treatment of N2 disease
because of the heterogeneity of nodal involvement. Also, patient
Figure 1: The IASLC lymph node map including the proposed grouping of lymph node stations into ‘zones’ for the purposes of prognostic analysis (Rusch et al. [3] with
permission).
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and tumour characteristics and extent of resection play a role in
the selection of treatment modality for these patients. In the
IASLC paper [9], 4277 of 11 619 patients clinically staged as
cN2cM0 underwent resection and had information on pN
category. Only a subgroup of 2876 patients underwent complete
(R0) resection without any induction therapy and had information
on nodal location and pN category based on pathological staging
from lymphadenectomy. An exploratory analysis of the impact of
Table 2: Anatomical definitions for each lymph node station and station grouping by nodal zones
Lymph node station Anatomical limits
Supraclavicular zone
#1: Low cervical, supraclavicular
and sternal notch nodes
Upper border: lower margin of cricoid cartilage.
Lower border: clavicles bilaterally and, in the midline, the upper border of the manubrium. 1R designates right-sided
nodes, and 1L left-sided nodes in this region.
For lymph node station 1, the midline of the trachea serves as the border between 1R and 1L.
Upper zone
#2: Upper paratracheal nodes 2R: Upper border: apex of the right lung and pleural space and, in the midline, the upper border of the manubrium.
Lower border: intersection of caudal margin of innominate vein with the trachea.
As for lymph node station 4R, 2R includes nodes extending to the left lateral border of the trachea.
2L: Upper border: apex of the lung and pleural space and, in the midline, the upper border of the manubrium.
Lower border: superior border of the aortic arch.
#3: Prevascular and retrotracheal
nodes
3a: Prevascular.
On the right: Upper border: apex of the chest. Lower border: level of carina. Anterior border: posterior aspect of the
sternum. Posterior border: anterior border of the superior vena cava.
On the left: Upper border: apex of the chest. Lower border: level of carina. Anterior border: posterior aspect of the
sternum. Posterior border: left carotid artery.
3p: Retrotracheal.
Upper border: apex of the chest. Lower border: carina.
#4: Lower paratracheal nodes 4R: includes right paratracheal nodes, and pretracheal nodes extending to the left lateral border of the tracheal.
Upper border: intersection of caudal margin of innominate vein with the trachea.
Lower border: lower border of the azygos vein.
4L: includes nodes to the left of the left lateral border of the trachea, medial to the ligamentum arteriosum.
Upper border: upper margin of the aortic arch.
Lower border: upper rim of the left main pulmonary artery.
Aorto-pulmonary zone
#5: Subaortic (aorto-pulmonary
window)
Subaortic lymph nodes lateral to the ligamentum arteriosum.
Upper border: the lower border of the aortic arch.
Lower border: upper rim of the left main pulmonary artery.
#6: Para-aortic nodes (ascending
aorta or phrenic)
Lymph nodes anterior and lateral to the ascending aorta and aortic arch.
Upper border: a line tangential to the upper border of the aortic arch.
Lower border: the lower border of the aortic arch.
Subcarinal zone
#7: Subcarinal nodes Upper border: the carina of the trachea.
Lower border: the upper border of the lower lobe bronchus on the left; the lower border of the bronchus
intermedius on the right.
Lower zone
#8: Para-oesophageal nodes
(below carina)
Nodes lying adjacent to the wall of the oesophagus and to the right or the left of the midline, excluding subcarinal
nodes.
Upper border: the upper border of the lower lobe bronchus on the left; the lower border of the bronchus
intermedius on the right.
Lower border: the diaphragm.
#9: Pulmonary ligament nodes Nodes lying within the pulmonary ligament.
Upper border: the inferior pulmonary vein.
Lower border: the diaphragm.
Hilar/interlobar zone
#10: Hilar nodes Includes nodes immediately adjacent to the mainstem bronchus and hilar vessels including the proximal portions of the
pulmonary veins and main pulmonary artery.
Upper border: the lower rim of the azygos vein in the right; upper rim of the pulmonary artery on the left.
Lower border: interlobar region bilaterally.
#11: Interlobar nodes Between the origin of the lobar bronchi.
a#11s: between the upper lobe bronchus and bronchus intermedius on the right.
a#11i: between the middle and lower bronchi on the right.
Peripheral zone
#12: Lobar nodes Adjacent to the lobar bronchi.
#13: Segmental nodes Adjacent to the segmental bronchi.
#14: Subsegmental nodes Adjacent to the subsegmental bronchi.
The International Association for the Study of Lung Cancer lymph node map. Adapted with permission from ref. [3].
#: nodal station number.
aOptional notations for subcategories of station.
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lymph node zones on survival was performed in a subgroup
(N = 1992 patients) from this cohort, ﬁnding that pathological
single N1 zone (pN1a) had better prognosis than multiple patho-
logical N1 zones (pN1b), that the prognosis of multiple patho-
logical N1 zones was the same as that of single pathological N2
zone (pN2a) and ﬁnally, that the prognosis of multiple pathologic-
al N2 zones (pN2b) was signiﬁcantly worse. Five-year survival
rates for pN1a, pN1b, pN2a and pN2b were 48, 35, 34 and 20, re-
spectively. These survival data should be interpreted with caution
and have already been misinterpreted. It is important to have in
mind that these survival analyses were performed in resected
patients with pathologically staged tumours and thus based on
results from lymphadenectomy: information on nodal status was
available from station 2 and from stations 4 to 9 in all contributing
institutions. Additionally, all centres but one provided documenta-
tion on stations 11 and 12, and most had information on stations
1, 13 and 14, while half of them provided documentation on
station 3. Therefore, the results from this highly selected pop-
ulation of patients used for this speciﬁc analysis cannot be extra-
polated to the clinical staging setting. This is why these data
cannot be invoked to propose upfront surgical treatment for
patients with presumed clinical single N2 zone determined with
the current clinical staging guidelines. No pretreatment test
[computed tomography (CT), positron emission tomography
(PET), endobronchial ultrasonography (EBUS), esophageal ultra-
sonography (EUS) and mediastinoscopy] can be compared with
lymphadenectomy, except the lymphadenectomies performed
through the transcervical approach (video-assisted mediastinal
lymphadenectomy—VAMLA and transcervical extended medias-
tinal lymphadenectomy— TEMLA). Therefore, there is room for a
well-designed prospective study to evaluate the possible role
of primary surgery in preoperatively proven single zone or single
station N2 disease.
There is a subgroup of patients with pretreatment histologically
proven N2 disease who are candidates for surgical multimodality
treatment. These patients are treated with induction chemotherapy
or induction chemoradiotherapy. In case of downstaging of the
mediastinal lymph nodes or major response in those lymph nodes
and in the tumour, resection with systematic nodal dissection can
be performed with acceptable morbidity and mortality and reward-
ing 5-year survival. There are several prognostic indicators, some of
which are related to the primary tumour and others are related to
the extent of nodal disease. To include patients for surgical multi-
modality treatment, the disease should be initially technically
resectable. Excluded for surgical multimodality are patients with
unresectable disease such as extracapsular disease (can be clearly
visualized by mediastinoscopy) or bulky N2 disease based on CT.
Fit patients with extracapsular disease and/or bulky N2 disease
should be treated with deﬁnitive chemoradiotherapy.
Bulky N2 disease is not well deﬁned but it correlates with the
radiographic group A, as described in the American College of
Chest Physicians (ACCP) Evidence-based Clinical Practice
Guidelines [10]. This group is deﬁned as mediastinal inﬁltration,
where the discrete lymph nodes cannot be distinguished or mea-
sured. Bulky is not strictly related to the size of the lymph nodes,
but it is considered by this committee that lymph nodes larger
than 25 mm short axis will also be deﬁned as bulky disease (Level
V). Bulky disease can be restricted to a single station, but usually
represents multistation or multiple zonal involvement. Since this
paper deals with preoperative lymph node staging, techniques to
obtain histology in bulky mediastinal nodal disease are beyond
the scope of this article.
PRIMARYMEDIASTINAL LYMPH NODE STAGING
Several techniques are available and their use depends on local
availability and local expertise.
These techniques include:
(i) imaging techniques,
(ii) endoscopic techniques and
(iii) surgical techniques.
Although we should aim for the test with the highest sensitivity
and NPV, the working group considers a rate of unforeseen pN2
disease of 10% as acceptable. After thorough mediastinal staging,
this unforeseen pN2 is mostly single station resectable nodal
disease.
Imaging techniques
Chest CT scan. CT remains important in lung cancer imaging.
However, due to its low sensitivity (55%) and speciﬁcity (81%), it is
impossible to solely rely on CT scan [10]. A CT scan may help us in
selecting the appropriate procedure for tissue sampling due to the
anatomical images it provides.
PET–CT scan. The addition of PET to CT results in more accurate
lymph node staging than CT alone with an overall sensitivity of
80–90% and speciﬁcity of 85–95%. PET–CT has a high NPV for
detecting mediastinal nodal disease in peripherally located
NSCLC. Exceptions include:
(i) suspected N1 nodes,
(ii) tumour >3 cm and
(iii) centrally located tumour without suspected nodes on CT or
PET scan.
(a) In a study from Japan [11], 30% of 143 patients with N1
disease on CT scan (lymph node short axis of >1 cm)
were found to have pathological N2–N3.
(b) A recent meta-analysis [12] has shown that the NPV of
PET–CT for tumours ≤3 cm was 94% (649 patients) com-
pared with 89% for tumours >3 cm (130 patients) staged
as T2 (6th edition of TNM). This ﬁnding was conﬁrmed in
a recent prospective study from Spain [13]. For peripheral
tumours ≤3 cm, the NPV of PET–CT was 92% while it was
85% for tumours >3 cm. Based on these studies, we now
recommend that for peripheral tumours (outer third of
the lung) ≤3 cm without enlarged (hilar and/or medias-
tinal) lymph nodes on CT and with PET-negative nodes,
further mediastinal staging can be omitted. There was a
substantial difference in the rate of mediastinal nodal dis-
ease between adenocarcinoma and other tumour hist-
ology (risk ratio 2.72). Also, high 18F-Fluorodeoxyglucose
(FDG) uptake in the primary lesion was associated with a
greater risk of occult nodal metastasis. For tumours >3 cm
(mainly adenocarcinoma with high FDG uptake), further
mediastinal staging techniques providing histology should
be considered (Fig. 2).
(c) Lee et al. [14] examined the prevalence of pathological
N2 disease in patients with clinical Stage I NSCLC (6th
edition of TNM version) with negative mediastinum on
PET and CT. In 2.9% of peripheral tumours (outer third of
lung), N2 disease was found, while the prevalence of N2
disease was 21.6% in central tumours.
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Diffusion-weighted magnetic resonance imaging. Advances
in magnetic resonance imaging (MRI) technology have allowed
acquisition of diffusion-weighted MRI (DWI), which provides
excellent tissue contrast because of the difference in the diffusion
of water molecules among tissues. The technique yields qualitative
and quantitative information that reﬂects changes at cellular level
and provides unique insights into tumour cellularity and the
integrity of cell membranes. In a recent meta-analysis [15], the
accuracy of DWI and 18F-FDG-PET–CT was evaluated. The pooled
sensitivity for DWI was 0.95 (95% CI 0.85–0.98) and signiﬁcantly
better than for FDG-PET–CT 0.89 (95% CI 0.85–0.91). However, at
this moment, there are no large prospective studies comparing the
value of DWI and FDG-PET and it is too early to determine the true
value of DWI in nodal staging in patients with NSCLC.
Endoscopic techniques
Conventional transbronchial needle aspiration. Although
the conventional transbronchial needle aspiration (TBNA) technique
has been available for almost three decades, its use in routine
clinical practice has been adopted only by a minority (10–15%) of
pulmonologists for mediastinal nodal staging of patients with
potentially resectable Stage I–III lung cancer. Major reasons for its
underuse are its dependency on nodal size (>15–20 mm short axis
on CT scan) and operator skills. Meta-analyses reported a sensitivity
of 78% and a false-negative rate of 28% for conventional TBNA
in clinical N2 disease with a high disease prevalence of 81% [16, 17].
A conventional blind TBNA is useful if it leads to proof of N3
disease, but too often does not exclude N3 disease in cases of
proven N2 disease.
Endoscopic ultrasonography: EUS-ﬁne-needle aspiration
and EBUS-TBNA
Practical aspects. Although E(B)US-TBNA is performed in some
centres under general anaesthesia, EBUS and EUS are more often
performed in an outpatient setting under local anaesthesia with
moderate sedation.
EBUS is able to visualize superior and inferior mediastinal LNs at
stations 2R/2L, 4R/4L and 7, as well as hilar LNs at stations 10, 11
and even 12, as described on the new LN map [3]. EUS particularly
visualizes superior mediastinal lymph nodes in station 4L and
inferior mediastinal nodes in stations 7, 8 and 9, as described
on the new LN map [3]. Thus, EUS-ﬁne-needle aspiration (FNA)
Figure 2: Revised ESTS guidelines for primary mediastinal staging.
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complements other techniques, as several of these LNs (stations 8
and 9) are not accessible by EBUS-TBNA or mediastinoscopy.
Although some expert centres considered EUS-FNA of lymph
nodes in stations 5 or 6, currently available data are limited, and
therefore, we do not recommend routine use of this procedure
for this indication [18].
It is possible to visualize and sample lymph nodes with a short
axis of >5 mm and the optimal number of aspirations per station
has been reported to be 3 [19]. When mediastinal nodal staging is
required, systematic nodal sampling is feasible by endosonogra-
phy. Indeed, several endosonography series have shown a mean
or median number of sampled mediastinal nodal stations of 3–4
per patient [20–26]. Nodal stations 4R, 4L and 7 should always be
sought during the endosonographic examination and described
in the medical report. In addition, the largest node measuring
>5 mm on ultrasonography within each of these stations as well as
FDG-avid nodes within each of these nodal stations should be
sampled for pathological analysis. On indication, nodal stations
10R and 10L can be biopsied. To avoid contamination while using
one single needle for an EBUS or EUS procedure, the order of
nodal sampling should begin at the level of N3 nodes followed by
N2 nodes before ending with N1 nodes.
Performance characteristics. Several meta-analyses of EUS-FNA
alone, EBUS-TBNA alone and combined EUS + EBUS reported a
pooled sensitivity of 83–94% for mediastinal staging of lung cancer
(Table 2) [27–31]. Only one randomized controlled trial (Aster trial,
20) has been performed, comparing the two staging strategies
proposed in the ESTS 2007 guidelines (either mediastinoscopy
or alternatively endosonography followed by mediastinoscopy) [1].
There was no difference in sensitivity or NPV when mediastinoscpy
was compared with endoscopic staging. However, the staging
strategy starting with combined endosonography and if negative
combining it with surgical staging has proved to detect signiﬁcantly
more mediastinal nodal N2/3 disease compared with media-
stinoscopy alone [20]. Another consequence is that the
implementation of endosonography for baseline mediastinal
nodal staging clearly reduces the need for mediastinoscopy [32].
On the other hand, the negative likelihood ratio reported by three
of the meta-analyses is 0.13–0.15 (Table 3) [29–31]. This implies
that the probability of having mediastinal nodal involvement for
any individual patient with a negative endosonography result is
13–15%. This probability based on endosonography alone is in
our opinion not low enough to directly proceed to a surgical
resection. Therefore, in the routine practice, we still recommend
a preoperative surgical staging procedure [i.e. video-assisted
mediastinoscopy (VAM)] in case of a negative endosonography.
However, there is evidence coming from prospective studies
performed in experienced endosonography centres that
mediastinoscopy may not improve sensitivity after a well-performed
negative endosonography with needle aspiration of at least three
mediastinal nodal stations in patients with low (<35%) prevalence of
mediastinal disease [21, 26, 33]. EBUS-TBNA and EUS-FNA are safe
procedures with reported minor complications in <1% of cases [27,
28, 34].With the rapidly increasing number of procedures, occasional
reports of moderate-to-severe complications have been published,
such as pneumothorax requiring chest tube drainage, infection of
bronchogenic cyst, empyema, lung and/or mediastinal abscess and
haemopneumomediastinum. So far, only one death has been
reported related to an EBUS-TBNA procedure [35].
Surgical staging techniques
Cervical mediastinoscopy. Cervical mediastinoscopy through
a pretracheal suprasternal incision was introduced by Carlens in
1959 and further popularized by Pearson in North America. It
allows a full mapping of the ipsilateral and contralateral superior
mediastinal lymph nodes. Cervical mediastinoscopy is performed
under general anaesthesia and can be safely done as an
outpatient procedure. For many years, it was the gold standard for
invasive staging of patients with potentially operable lung cancer.
Since 1995, use of video techniques has been introduced leading
to VAM. VAM clearly improved visualization and teaching [36]
since both the trainer and the trainee can share the magniﬁed
image on the monitor. For more details on the technique of
cervical mediastinoscopy, we refer to a recent publication on this
topic [37].
There are only retrospective studies comparing the safety and
accuracy of conventional mediastinoscopy with VAM (Table 4).
Although some authors [40, 42, 43] found an increase in the
number of LN or LN stations biopsied, no difference in sensitivity
or NPV was found (Table 4). In some of these studies, a reduction
in the complication rate (mainly of recurrent nerve palsy) was
observed. Very recently [44], a best evidence topic has been
published on the safety and accuracy of VAM compared with con-
ventional mediastinoscopy (Table 5). The authors analysed 108
papers published between 1989 and 2011. There were 5156
conventional mediastinoscopies and 956 VAMs. Both procedures
Table 3: Published meta-analyses on endobronchial and oesophageal endosonography with FNA for mediastinal nodal staging of
lung cancer
Author Year Modality Patients (n) Pooled sensitivity
% (95% CI)
Pooled specificity
% (95% CI)
NLR
Micames et al. [27] 2007 EUS 1201 83 (78–87) 97 (96–98) –
Gu et al. [28] 2009 EBUS 1298 93 (91–94) 100 (99–100) –
Adams et al. [29] 2009 EBUS 817 88 (79–94) 100 (92–100) 0.12
Chandra et al. [30] 2012 EBUS 1658a 92 (90–93) 100 (97–100) 0.13
Zhang et al. [31] 2013 EUS + EBUS 823 86 (82–90) 100 (99–100) 0.15
aSome small series also included sarcoidosis.
n: number; EUS: esophageal ultrasonography; EBUS: endobronchial ultrasonography; NLR: negative likelihood ratio.
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are safe with no mortality in that time frame and a low morbidity.
Although by VAM more lymph node stations are sampled, the
NPV and accuracy were identical.
Although the videomediastinoscope is not strictly necessary to
achieve a thorough, clinically acceptable mediastinoscopy, it has
many advantages over the conventional one: larger and clearer
images, the possibility to simultaneously share the procedure with
trainees and all personnel in the operative theatre, the possibility
to record the operation for future educational uses and discussion
and the possibility to improve its teaching without compromising
the safety or accuracy of the procedure. Moreover, it allows bi-
manual dissection with possibilities to perform nodal dissection
and removal rather than sampling or biopsy. This is especially im-
portant and technically feasible for the subcarinal LN station. After
removal of station 7 LNs, the oesophagus can be clearly visualized.
The ESTS working group recommends performing VAM.
Video-assisted thoracoscopic surgery. Although video-
assisted thoracoscopic surgery (VATS) can reach almost every
mediastinal lymph node station, it is more invasive than cervical
mediastinoscopy (it needs double lumen intubation), it is limited
by pleural adhesions and it can evaluate only ipsilateral nodal
disease. For the para-aortic lymph nodes (station 6) and the
subaortic lymph nodes (station 5), left VATS is a surgical technique
that allows obtaining large tissue samples. It is indicated when
enlarged PET-positive lymph nodes are visualized at Level 5 or
6. These lymph node stations cannot be biopsied by routine
mediastinoscopy, E(B)US-FNA. An alternative to VATS is the
left anterior mediastinotomy. In some experienced centres,
extended mediastinoscopy is performed for these lymph node
stations and it gives good NPVs: 0.89–0.97 [37]. Extended
cervical mediastinoscopy is performed from the mediastinoscopy
incision [45].
VAMLA and TEMLA. During the last decade, two new invasive
staging techniques representing more radical methods of
mediastinal exploration have been introduced: VAMLA [46] and
TEMLA [47]. These two techniques aim for a complete removal of
all mediastinal nodes with the surrounding adipose tissue
to improve the accuracy of staging. VAMLA is completely
performed with the use of a videomediastinoscope, whereas
TEMLA uses a 5- to 8-cm collar incision in the neck and elevates
the sternum with a hook. The dissection is performed in an open
way and with the use of a videomediastinoscope. By VAMLA, the
lymph nodes which are usually accessible through mediastinoscopy
are removed. By TEMLA, more lymph node stations are accessible
Table 4: Staging values of conventional mediastinoscopy and videomediastinoscopy
Author and reference Type of mediastinoscopy n Sensitivity NPV Diagnostic accuracy
Rami-Porta and Call [37] CM 148 0.78 0.85 0.90
VAM 137 0.86 0.90 0.94
Venissac et al. [38] VAM 240 0.91 NA 0.98
Lardinois et al. [39] VAM after induction 24 0.81 NA 0.91
VAM without induction 195 0.87 NA 0.95
Leschber et al. [40] CM 52 NA 0.81 0.84
VAM 119 NA 0.83 0.88
Karfis et al. [41] VAM 87 0.8 0.59 0.85
Anraku et al. [42] CM 505 0.92 0.95 0.97
VAM 140 0.95 0.98 0.98
Cho et al. [43] CM 222 0.70 0.95 0.96
VAM 299 0.75 0.96 0.96
Adapted from Rami-Porta and Call [37].
CM: conventional mediastinoscopy; n: number of patients; NA: not available; NPV: negative predictive value; PPV: positive predictive value; VAM: video-
assisted mediastinoscopy.
Table 5: Overall comparison VAM vs CM (studies 1989–2011)
VAM (n = 956) CM (n = 5156) P-value
Mortality 0 0
Morbidity 0.83–2.9% 0–5.3% NS
No. of LN biopsied 6–8.5 5–7.13 NS
No. of LN stations sampled 1.9–3.6 2.6–2.98 NS
Accuracy 87.9–98.9% 83.8–97.2% NS
NPV 83.0–98.6% 81.0–98.7% NS
Adapted from Zakkar et al. [44].
CM: conventional mediastinoscopy; NPV: negative predictive value; VAM: video-assisted mediastinoscopy.
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such as the prevascular, the para-aortic, the subaortic and the
para-oesophageal lymph node stations. The NPV is very high and
approaches 98.7% for TEMLA. The results of VAMLA and TEMLA
regarding sensitivity and side effects are shown in Table 4. Although
there is no doubt that the accuracy of mediastinal staging increases
when lymphadenectomy is performed compared with nodal
biopsy, these techniques have a higher morbidity and mortality.
The complications after VAMLA and TEMLA are well recorded
(Table 6) and are probably more studied in detail than after CM or
VAM. These procedures are performed in very experienced centres.
For VAMLA, mainly problems with recurrent nerve palsy and
important scarring with an impact on subsequent resection are
reported. The published data for TEMLA are mainly from one very
experienced centre and there are concerns on morbidity and
mortality.
For TEMLA and VAMLA, we conclude that currently available
data regarding its use are limited and, therefore, we do not
recommend its use except of clinical trials. We encourage
other centres to publish their data with these new staging
techniques.
MINIMAL REQUIREMENTS FORMEDIASTINAL
NODAL STAGING
The ESTS clinical practice guidelines 2013 for preoperative medi-
astinal nodal staging recommend that at least the following nodal
stations should be explored and biopsied:
(i) right and left lower paratracheal lymph nodes (stations 4R and
4L) and
(ii) subcarinal lymph nodes (station 7).
If present, the right and left upper paratracheal stations 2R and
2L should also be biopsied.
When required to determine subsequent treatment strategy,
lymph node stations 10R (below the azygos vein) and 10L
(below the upper rim of left pulmonary artery) should be biop-
sied. In case of left-sided tumours, stations 5 and 6 should be
biopsied if it changes the treatment strategy. The same applies
to the lower mediastinal lymph nodes (stations 8 and 9). Nodal
biopsy of these stations could be indicated in case extracapsular
(non-resectable) nodal disease is expected from imaging
studies.
ALGORITHM FOR PRIMARYMEDIASTINAL
STAGING
The algorithm for preoperative mediastinal staging is shown in
Fig. 2. For NSCLC, both for mediastinal and for distant staging, PET
or PET–CT is indicated.
(i) Direct surgery can be performed if all of these three criteria
apply: no suspect lymph node detected by CT or PET, a
tumour of ≤3 cm (Stage IA), located in the outer third of the
lung (Level IIA).
(ii) In case of enlarged mediastinal lymph nodes on CT or
PET-positive lymph nodes, tissue conﬁrmation is indicated. In
this case, endosonography (EBUS/EUS) with FNA is the ﬁrst
choice (when available) since it is minimally invasive and has
a high sensitivity to rule in mediastinal nodal disease (Level
IA). If negative, video-assisted mediastinoscopy is indicated
(Level IB). The combined use of endoscopic staging and sur-
gical staging results in the highest accuracy. For patients with
a left upper lobe tumour, surgical staging of the aorto-
pulmonary window nodes (if enlarged on CT and/or PET–
CT-positive) can be performed (by anterior mediastinotomy,
VATS or extended cervical mediastinoscopy) if involvement
changes treatment strategy (Level V).
(iii) Invasive staging by E(B)US/mediastinoscopy is indicated if at
least one of these criteria applies: central lesion, suspect N1
nodes (Level IIB). In case of tumours >3 cm (mainly in adeno-
carcinoma with high FDG uptake), the NPV for mediastinal
nodal disease is <90% and invasive staging may be considered
(Level IIB). Although a high FDG update in the primary
tumour is a predictor of N2 disease, the ideal cut-off of stan-
dardized uptake value (SUV) has not yet been determined
above which invasive mediastinal nodal staging is required. In
addition, the SUV measurement is not yet standardized from
Table 6: Results of VAMLA and TEMLA
Author Procedure n NPV Sensitivity Side effect
Hürtgen et al. [46] VAMLA 46 100% 100% Recurrent laryngeal nerve palsy: 2.2%
Scarring with impact on subsequent resection: 25%
Leschber et al. [48] VAMLA 23 100% 100% Blood loss >100 ml : 12%
Witte et al. [49] VAMLA 144 NA 100% Recurrent laryngeal nerve palsy: 3.4%
Vascular lesions: 2.1%
Mediastinitis: 0.7%
Marked scarring: 19%
Zielinski et al. [50] TEMLA 256 97.4% 94% Mortality: 0.3%
Recurrent laryngeal nerve palsy: 2.5%
Pneumothorax: 0.7%
Pleural effusion: 1.1%
Yoo et al. [51] VAMLA 108 NA NA Recurrent laryngeal nerve palsy: 3.4%
n: number of patients; NPV: negative predictive value; VAMLA: video-assisted mediastinal lymphadenectomy; NA: not available; TEMLA: transcervical
extended mediastinal lymphadenectomy.
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one centre to another, and therefore, a visual interpretation
of the FDG uptake on PET is to be preferred [52]. In all of the
above-mentioned cases, there is the choice between VAM
with biopsy or lymph node dissection or endoscopic staging
by EBUS/EUS with FNA. The choice depends on local expert-
ise to adhere to minimal requirements for staging (Level V). If
video-assisted mediastinoscopy is negative, these patients
can undergo surgical treatment. They also can undergo surgi-
cal treatment after negative EBUS/EUS if the number of nodes
explored and the number of needle passes in each node
meet the established requirements. Otherwise, surgical ex-
ploration is recommended after negative EBUS/EUS.
(iv) If only CT is available, we refer to the algorithm of the 2007
edition of the ESTS guidelines [1].
MEDIASTINAL RESTAGING AFTER INDUCTION
THERAPY
Mediastinal downstaging after induction therapy for locally
advanced Stage III NSCLC is an important prognostic factor for
long-term survival. Patients with persisting mediastinal involve-
ment have a worse prognosis compared with those with proven
mediastinal downstaging.
The same techniques used in primary staging can be used for
mediastinal restaging. Non-invasive imaging techniques are not
accurate enough for mediastinal restaging. PET provides additional
metabolic information, but there are conﬂicting data regarding its
use. PET has been shown to be more accurate in predicting the T
component than the N status [52]. Although experience is rather
limited, integrated PET–CT combining precise anatomical and
functional information seems to be more accurate for restaging
[53]. In a prospective study of 93 patients who were restaged by
chest CT and integrated PET–CT after induction chemoradiother-
apy, repeat PET–CT was found to be more accurate than CT alone
for all pathological stages [54]. However, there were 20% false-
negative and 25% false-positive cases. So, in case of suspicion of
residual mediastinal disease, nodal biopsies are still required [54].
Different techniques providing histology can be used for re-
staging (Tables 7 and 8). Endoscopic techniques can be used, but
EBUS-TBNA reported a variable NPV of 20 [56] and 78% [58]. The
difference in the NPV may be explained by the prevalence of
ypN2 after induction therapy, which was 94% in the study of
Herth and 44% in the study of Szlubowski. These results empha-
size that a negative EBUS for restaging should be conﬁrmed by in-
vasive surgical mediastinal restaging.
Remediastinoscopy (reMS) was found to be technically feasible,
also after induction therapy [59, 62]. However, reMS is used only
in very selected experienced centres and is not widely adoptable
due to severe ﬁbrosis. Although feasible, the accuracy is lower
than that of mediastinoscopy for primary staging and this ques-
tions the timing of mediastinoscopy (baseline or at restaging,
timing of further radiotherapy after induction which should not
be delayed).
In experienced hands, TEMLA is also an accurate restaging tech-
nique. In a series of 63 patients, induction chemotherapy (n = 54)
or chemoradiotherapy (n = 9) was administered for N2 or N3
NSCLC. Initial mediastinoscopy was performed in 7 patients.
Sensitivity, speciﬁcity and accuracy of TEMLA were 95.5, 100 and
Table 7: Restaging with EUS and EBUS after induction therapy
Technique Author n Sensitivity Specificity Accuracy
EBUS Krasnik et al. [55] 83 0.70 1.0 0.75
EBUS Herth et al. [56] 124 0.76a 1.0 0.77
EUS Stigt et al. [57] 25 0.92 1.0 0.92
EBUS Szlubowski et al. [58] 61 0.67 0.86 0.80
EUS von Bartheld et al. [18] 58 0.44 NR 0.60
aNegative predictive value was only 20%.
EUS: endoscopic (oesophageal) ultrasound; EBUS: endobronchial ultrasound; n: number of patients; NR: not reported.
Table 8: Restaging with repeat mediastinoscopy after induction therapy
Author and reference n IT Morbidity (%) Mortality (%) Sensitivity Negative predictive value Accuracy
Stamatis et al. [59] 165 CT-RT 2.5 0 0.74 0.86 0.93
De Leyn et al. [53] 30 CT 0 0 0.29 0.52 0.60
De Waele et al.a [60] 104 CT (n = 79) CT-RT (n = 25) 3.9 1 0.70 0.73 0.84
Marra et al. [61] 104 CT-RT 1.9 0 0.61 0.85 0.88
Call et al. [45] 84 CT (n = 49) CT-RT (n = 35) 4.0 1 74 0.79 0.87
aCombined, updated series.
n: number of patients; IT: induction therapy; CT: chemotherapy; CT-RT: chemoradiotherapy.
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98.3%, respectively [63]. In a recent retrospective analysis from the
same institution, EBUS/EUS and TEMLA performed for restaging
after neoadjuvant treatment were compared in 78 patients.
Sensitivity, speciﬁcity and NPV of TEMLA were 97, 100 and 99%,
respectively [50].
Owing to severe ﬁbrosis, reMS should not be attempted after
VAMLA or TEMLA.
Only one study reported the results of VATS for restaging after
induction therapy [64]. In this Cancer and Leukemia Group B
39 803 trial, a negative result of VATS was deﬁned as negative
lymph node biopsies from at least three lymph node stations,
whereas a positive result consisted of a pathological proof of per-
sisting N2 disease or the demonstration of pleural carcinomatosis.
Sensitivity, speciﬁcity and NPV of VATS for restaging were 67, 100
and 73%, respectively. Restaging by VATS is feasible, but requires
single-lung ventilation and is limited to one hemithorax only.
An alternative approach that needs prospective validation is to
rely on endosonography for baseline mediastinal nodal staging
and a ﬁrst mediastinoscopy for restaging after induction therapy.
In this ‘restaging’ setting, the NPV of ‘a ﬁrst and more easy and
safe mediastinoscopy’ was 90% (with a prevalence of ypN2
of 46%) [39].
We conclude that optimal mediastinal lymph node staging is
a truly multidisciplinary process, with a variety of possible techni-
ques, to be performed by experienced hands.
Conﬂict of interest: none declared.
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